Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2022 06:05 ET | Source: MannKind

MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30

Simplified 2x dose of Technosphere® Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutesHigher dose of TI resulted in a mean difference of...
March 28, 2022 06:05 ET | Source: MannKind

MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference

DANBURY, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
March 22, 2022 06:05 ET | Source: MannKind

MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit

DANBURY, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
March 08, 2022 06:05 ET | Source: MannKind

MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference

DANBURY, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
February 24, 2022 16:00 ET | Source: MannKind

MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results

Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million; +13% vs. 4Q 2020$260.7 million of Cash, Cash...
February 24, 2022 06:05 ET | Source: MannKind

Update on Tyvaso DPI™ New Drug Application

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
February 21, 2022 09:05 ET | Source: MannKind

MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its...
February 10, 2022 06:05 ET | Source: MannKind

MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference

DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
January 05, 2022 06:10 ET | Source: MannKind

MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference

DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
January 05, 2022 06:05 ET | Source: MannKind

MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind’s CEO appointed as a member of the Thirona...